RxDoctor Payments DataLook up a doctor →

Scott Phillips, MD

Interventional Cardiology · Anderson, SCNPI 1457394868

Payments from drug & device makers

$11,012in general payments, 2019–2025

Across 646 payments — averaging $17.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Inari Medical, Inc.$1K
  • Johnson & Johnson$1K
  • Abiomed$894
  • AstraZeneca$763
  • Abbott$762
  • plus $5K from 44 others

What the payments were for

  • Food & beverage$10,90299%
  • Education$1101%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,012 in reported general payments places this provider in the 50th percentile of 117 interventional cardiology providers in South Carolina.

See all interventional cardiology providers in South Carolina

Medicare billing

Part B allowed, 2024
$222,279
Medicare patients
2,545
Services billed
4,790

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban323$381,247
EntrestoSacubitril/Valsartan50$75,289
Repatha SureclickEvolocumab63$45,838
XareltoRivaroxaban25$35,989
FarxigaDapagliflozin Propanediol13$15,189
BrilintaTicagrelor22$13,862
MultaqDronedarone Hcl11$8,327
Valsartan130$4,894
Prasugrel Hcl71$4,188
Rosuvastatin Calcium208$3,380
Ranolazine ErRanolazine24$2,938
Metoprolol Succinate153$2,308
Diltiazem 12hr ErDiltiazem Hcl12$2,152
Carvedilol226$2,134
Propafenone Hcl32$2,112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$501$381,247323 claims
NovartisEntresto$1,284$75,28950 claims
Johnson & JohnsonXarelto$1,006$35,98925 claims
AstraZenecaFarxiga, Brilinta$763$29,05135 claims
Sanofi-aventis U.S. LLCMultaq$120$8,32711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 117 interventional cardiology providers in South Carolina.

Other interventional cardiology in Anderson

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →